Bull & Bear
Bull and Bear
Verdict: Watchlist — the decisive variable is genuine cyclical recovery, and it is not yet observable. Somero is a clean, net-cash, 80%-share laser-screed monopoly trading at roughly 3x mid-cycle EBITDA — which is exactly what you would expect at a cyclical bottom or at the start of a structural decline, and the two look identical until the next print. The single tension that matters is whether FY2022's $133.6M was a COVID-era warehouse peak that caps the business or a spike the company mean-reverts away from: management itself guides FY2026 down to ~$86M and refuses to forecast recovery, so today the burden of proof sits with the Bull and is unmet. What would change the conclusion is concrete and dateable — a second consecutive up-half in North American Boomed + Ride-on screed revenue (77% of sales, the most operating-leveraged line) with operating margin expanding back toward 20% and gross margin holding at or above 52%. Until that print, the net-cash floor and clean forensics keep this off the "avoid" pile, but the impaired income bid and broken governance keep it off the "buy" pile.
Bull Case
Source: bull-claude.md, drawing on the Moat, Financials and Forensic tabs.
Dropped: the Bull's fourth point — that the activist accumulation and mid-July governance review form a "dateable activist-long catalyst" — is the weakest, because it is a catalyst-calendar argument rather than a durable thesis variable, and the unlock it promises is contested by the same broken-vote backdrop the Bear cites.
Bull-case fair value: ~$4.50 per share (≈ $245M equity value), about 85% above the ~$2.45 USD-equivalent current price (193p on AIM). Method: ~7.5x mid-cycle EV/EBITDA on ~$30M normalized EBITDA plus $33M net cash, on 54.6M shares — a re-rate from ~3x trough to a still-conservative normalized multiple, contingent on a cycle turn in US private non-residential construction over ~18–24 months. What would refute it: gross margin breaking below ~50% on a non-volume basis, which would mean Ligchine/Chinese price pressure or Hammerhead dilution is eroding the pricing power that is the entire quality case.
Bear Case
Source: bear-claude.md, drawing on the Financials, Research, People and Story tabs.
Dropped: the Bear's fourth point — "growth only where the moat fails" (Europe −39%, Hammerhead dilution) — is the weakest as a standalone, because it argues against growth optionality the core thesis does not require; it is more powerful folded into the margin tension below than as a separate reason to be short.
Bear-case downside: ~145p (≈ the 145.5p all-time low), about 25% below the 193p quote — implied market cap ~$102M, EV ~$69M. Method: structural re-rating to a peer-trough ~4.3x EV/EBITDA (Gencor, the net-cash cyclical twin, trades 4.8x) on normalized EBITDA of ~$15–16M plus $33M net cash, cross-checked against the 145.5p technical floor and ~1.2x tangible book, over the FY2026 results cycle (~12–18 months). What would invalidate it: a second consecutive up-half in North American Boomed + Ride-on screed revenue with operating margin expanding back toward 20% and gross margin holding at or above 52% — a genuine volume-led recovery — or a governance resolution delivering a redomicile plus a large capital return.
The Real Debate
Source: synthesized from bull-claude.md and bear-claude.md; underlying figures from the Financials, Moat, People and Research tabs.
All three tensions rest on the same root fact — a 33% revenue fall to FY2015 dollars — read two ways. The first is the parent: if revenue is a trough, the Bull wins the valuation and margin arguments almost automatically; if it is a plateau, the Bear's "16x on the right earnings" frame holds and the net cash becomes a slow leak into M&A and pay rather than a floor.
Verdict
Watchlist. The debate is close, but today the weight sits marginally with the Bear, for one disciplined reason: the entire long thesis underwrites an earnings level — mid-cycle mean reversion — that management itself will not forecast, guiding FY2026 down to ~$86M, while the marginal buyer on a thin, single-analyst AIM micro-cap has been removed by a ~40% dividend cut. The deciding evidence for the trough-versus-structural-reset tension is forward, not in the report. The Bull can still be right, and powerfully so: this is a real 80%-share monopoly with a 52% gross margin and clean forensics, net cash worth ~28% of market value protects the downside, and at ~3x mid-cycle EBITDA the asymmetry is real if the cycle turns — which is why this is a Watchlist and not an Avoid. The durable thesis-breaker to watch is gross margin breaking below ~50% on a non-volume basis (structural erosion of pricing power, not timing); the near-term marker that would flip this to Lean Long is a second consecutive up-half in North American Boomed + Ride-on screed revenue with operating margin rebuilding toward 20% and gross margin holding at or above 52%. Conversely, an FY2026 revenue plateau at or below ~$86M alongside an advisory-only July governance outcome confirms the Bear and moves this toward Avoid.
Watchlist: a clean, net-cash monopoly cheap enough to matter, but the thesis underwrites a recovery management itself won't forecast — wait for a second consecutive up-half in North American screed revenue with gross margin holding at or above 52% before leaning long.
</content> </invoke>